While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Gilead Sciences, Inc. (GILD) witnessed a slew of price target hikes on Friday after the company raised its annual product sales and earnings outlook on strong HIV product sales. Truist upgraded Gilead ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has ...

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

GILEAD SCIENCES INC (GILD) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...

Gilead Sciences (GILD) has outperformed the market over the past 20 years by 4.08% on an annualized basis producing an average annual return of 12.81%. Currently, Gilead Sciences has a market ...